Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, announced results from two Phase 1/2 clinical trials evaluating ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". FRAMINGHAM, Mass., Sept. 18, 2020 /PRNewswire/ -- BERG, a clinical-stage ...
Lugano, Switzerland, 23 May 2025 – The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that ...
SAN DIEGO and CALGARY, AB, Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY),( Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today ...
The GOBLET Phase 1/2 Simon two-stage basket study was designed to evaluate pelareorep in combination with the PD-L1 inhibitor atezolizumab (atezo) and chemotherapy in patients with different solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results